Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Empl ...

Cytosorbents Corporation (NASDAQ:CTSO) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Amy Vogel – Investor Relations Phillip Chan – Chief Executive Officer Kathleen Bloch – Chief Financial Officer Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-Cytosorbents Europe GmbH Christopher Cramer – Vice President-Business Development Efthymios Deliargyris – Chief Medical Officer Vincent Capponi – Chief Operating Officer and President Mike Gibson ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer ...

CytoSorbents Corporation Annual Shareholders Meeting June 7, 2022 AGAAGAAAAAAAAAAAAAAAAA Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forwardlooking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant ...

Cytosorbents Corporation (NASDAQ:CTSO) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations & Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President & Chief Operating Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales & Marketing and Managing Director of Cytosorbents Europe Christopher Cramer - Vice President, Business Development Efthymios Del ...

| --- | --- | --- | --- | |-------|-------|-------|---------------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | First Quarter 2022 Earnings Conference Call | | | | | CytoSorbents Corporation | | | | | May 3, 2022 | Conference Call Participants Moderator: Terri Anne Powers CytoSorbents Corporation Phillip Chan, MD, PhD – Chief Executive Officer Vincent Capponi, MS – President and Chief Operating Officer Kathleen Bloch, MBA, CPA – Chief Financial Officer Efthymios " ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 (Nasdaq Capital Market) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-kn ...

Cytosorbents Corporation (NASDAQ:CTSO) Q4 2021 Earnings Conference Call March 8, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations and Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President, Sales and Marketing and Managing Director, CytoSorbents Europe Christopher Cramer ...

HELPING TO TREAT INFLAMMATION AND DEADLY CONDITIONS IN INTENSIVE CARE AND CARDIAC SURGERY CytoSorbents Corporation - NASDAQ: CTSO SVB Leerink Global Healthcare Conference – February 2022 Safe Harbor Statement This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or ach ...